Calidi Biotherapeutics, Inc. CLDI
1.13
(0.07)
(5.83%)
as of 25 Sep
- Market cap
- $3.0M
- P/E
- 0.0×
Follow CLDI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1,970.77% | (893.28%) | (408.86%) | (900.56%) | |
| (247.70%) | (222.05%) | (202.88%) | (283.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(383.30%) | (824.60%) | (585.03%) | (790.80%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(70.97) | (79.63) | (28.55) | (12.60) | |
Free Cash Flow |
(21.77) | (21.41) | (18.40) | (17.84) | |
Capital Expenditures |
(0.10) | (0.12) | (0.12) | (0.09) | |
Piotroski F-Score |
3.00 | 2.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(117.97%) | (210.20%) | (148.44%) | (222.86%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.85 | 0.83 | 0.73 | 0.76 | |
Depreciation/Fixed assets |
1.91 | 2.11 | 2.22 | 2.21 | |
Capex/Depreciation |
(0.06) | (0.07) | (0.07) | (0.05) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(70.66) | (79.19) | (28.37) | (12.54) | |
Capex per Share |
(0.31) | (0.45) | (0.18) | (0.07) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates